Conditions: Schizophrenia
Keywords: Open-label extension Ziprasidone study in Schizophrenia
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 344
Healthy volunteers: no

Brief summary:
To provide treatment to eligible subjects who have successfully completed one of the following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or A1281088 (NCT00143351).

Detailed description:

Arms:

Interventions: intervention 1: Ziprasidone
Intervention descriptions: intervention 1: 20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.

Protocol document: